Technical Analysis for PCRX - Pacira Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 40.78 3.45% 1.36
PCRX closed up 3.45 percent on Tuesday, March 19, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical PCRX trend table...

Date Alert Name Type % Chg
Mar 19 20 DMA Support Bullish 0.00%
Mar 19 Multiple of Ten Bullish Other 0.00%
Mar 18 Crossed Above 20 DMA Bullish 3.45%
Mar 18 Crossed Above 50 DMA Bullish 3.45%
Mar 18 MACD Bullish Signal Line Cross Bullish 3.45%
Mar 18 180 Bullish Setup Bullish Swing Setup 3.45%
Mar 15 20 DMA Resistance Bearish 5.59%
Mar 15 Fell Below 50 DMA Bearish 5.59%
Mar 15 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.59%
Mar 15 Multiple of Ten Bearish Other 5.59%

Older signals for PCRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers worldwide. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company markets EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia; and DepoCyt(e), a liposomal formulation of the chemotherapeutic agent cytarabine indicated for the intrathecal treatment of lymphomatous meningitis, a cancer of the immune system. Its product pipeline comprise EXPAREL that has completed Phase II clinical trials for postsurgical analgesia-nerve block administration; DepoNSAID, which is in preclinical trials for the relief of acute pain; and DepoMethotrexate that is in preclinical trials for the treatment of rheumatoid arthritis and oncology, as well as Bupivacaine Liposome Injectable Suspension for veterinary postsurgical analgesia. Pacira Pharmaceuticals, Inc. has a development and commercialization agreement, and related supply agreement with Aratana Therapeutics, Inc. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Medicine Health Cancer Pharmaceutical Pain Surgery Pharmaceutical Products Pharmaceutical Industry In China Pharmacology Rheumatoid Arthritis Dosage Forms Piperidines Drug Delivery Technology Bupivacaine Liposome Surgical Site
Is PCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 55.0
52 Week Low 26.95
Average Volume 605,935
200-Day Moving Average 42.4116
50-Day Moving Average 39.0924
20-Day Moving Average 39.301
10-Day Moving Average 38.274
Average True Range 1.7578
ADX 13.7
+DI 30.5444
-DI 19.8002
Chandelier Exit (Long, 3 ATRs ) 40.1466
Chandelier Exit (Short, 3 ATRs ) 40.3434
Upper Bollinger Band 42.2959
Lower Bollinger Band 36.3061
Percent B (%b) 0.75
BandWidth 15.240834
MACD Line -0.1204
MACD Signal Line -0.301
MACD Histogram 0.1807
Fundamentals Value
Market Cap 1.65 Billion
Num Shares 40.4 Million
EPS -1.72
Price-to-Earnings (P/E) Ratio -23.71
Price-to-Sales 4.67
Price-to-Book 5.03
PEG Ratio -3.43
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 43.47
Resistance 3 (R3) 43.22 42.06 43.02
Resistance 2 (R2) 42.06 41.38 42.19 42.87
Resistance 1 (R1) 41.42 40.95 41.74 41.68 42.72
Pivot Point 40.27 40.27 40.43 40.40 40.27
Support 1 (S1) 39.63 39.58 39.95 39.88 38.84
Support 2 (S2) 38.47 39.16 38.60 38.69
Support 3 (S3) 37.83 38.47 38.54
Support 4 (S4) 38.09